Skip to main content
Bliss GVS Pharma Limited logo

Bliss GVS Pharma Limited — Investor Relations & Filings

Ticker · BLISSGVS ISIN · INE416D01022 LEI · 335800GXY3YCGGP7KJ45 BSE.NS Manufacturing
Open in API
Filings indexed 1,236 across all filing types
Latest filing 2026-04-09 Regulatory Filings
Country IN India
Listing BSE.NS BLISSGVS

About Bliss GVS Pharma Limited

https://blissgvs.com/

Bliss GVS Pharma Limited specializes in the development, manufacturing, and marketing of diverse pharmaceutical formulations. The company is a global leader in the production of suppositories and pessaries, maintaining an extensive portfolio within these specialized dosage forms. Its therapeutic focus includes anti-malarials, anti-fungals, anti-bacterials, anti-inflammatories, and gastrointestinal treatments. The organization operates state-of-the-art manufacturing facilities compliant with international quality standards, including WHO-GMP. With a strategic focus on emerging markets, the company distributes its range of prescription and over-the-counter products across Sub-Saharan Africa, Southeast Asia, and Latin America, leveraging a robust supply chain to provide accessible healthcare solutions.

Recent filings

Filing Released Lang Actions
Please find enclosed herewith the Postal Ballot Notice regarding the appointment of an Independent Director of the Company.
Regulatory Filings Classification · 95% confidence The document is a detailed Notice of Postal Ballot issued by Bliss GVS Pharma Limited, dated April 9, 2026. It is addressed to stock exchanges and shareholders, disclosing the intention to seek shareholder approval via remote e-voting for the appointment of two independent directors. The document references compliance with SEBI Listing Regulations, Companies Act provisions, and related circulars. It includes the full text of the postal ballot notice, explanatory statements, voting instructions, and details about the voting period and scrutinizer appointment. This is not a report of voting results, nor a brief announcement, but the full notice seeking shareholder consent. It is not an annual report, earnings release, or management report. It is a regulatory disclosure under SEBI Regulation 30 about a postal ballot notice. According to the filing definitions, such a document fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit other specific categories like Declaration of Voting Results (DVA) or Proxy Solicitation (PSI). The document is substantive and lengthy (15,000 characters), not a short announcement or certification. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2026-04-09 English
Shareholders meeting
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice of a Postal Ballot issued by Bliss GVS Pharma Limited, dated April 9, 2026. It is addressed to stock exchanges and shareholders, disclosing the intention to seek shareholder approval via remote e-voting for the appointment of two independent directors. The document references compliance with SEBI Listing Regulations, Companies Act provisions, and related circulars. It includes the full text of the notice, explanatory statements, voting instructions, and procedural details. It is not a report of voting results, nor a brief announcement, but the actual notice and explanatory material sent to shareholders to solicit votes. This fits the definition of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings or resolutions. The document is lengthy (15,000 characters), contains substantive content, and is not merely an announcement or certification. Therefore, the correct classification is PSI with high confidence.
2026-04-09 English
Please find enclosed herewith the Intimation regarding the Credit Rating received by the Company from Investment Information and Credit Rating Agency of India Limited (ICRA).
Capital/Financing Update Classification · 95% confidence The document is an official communication from Bliss GVS Pharma Limited to stock exchanges regarding a credit rating assigned by ICRA Limited. It includes details of the rating action on the company's financial instruments and a letter from ICRA explaining the rating and its terms. The document is an update on the company's credit rating, which relates to financing and capital structure information. It is not a full financial report, earnings release, or management discussion. The content fits the category of Capital/Financing Update (CAP) as it informs about credit rating changes affecting the company's debt instruments.
2026-04-08 English
Credit Rating- New
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to stock exchanges regarding a credit rating assigned by ICRA Limited to the company's financial instruments. It includes details of the rating action, the rated amount, and the rating letter from ICRA. The content is an update on the company's credit rating status, which is a form of capital/financing update rather than a financial report, earnings release, or regulatory filing. The document is about the credit rating assigned to debt instruments, which fits best under Capital/Financing Update (CAP). The document length is over 6,000 characters and contains substantive information about the rating action, not just an announcement of a report publication or a certification. Therefore, the appropriate classification is CAP with high confidence.
2026-04-08 English
Copy of Newspaper Publication
Regulatory Filings
2026-04-06 English
Please find enclosed herewith the Newspaper Advertisement published on April 04, 2026.
Regulatory Filings
2026-04-06 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.